Skip to main content

Table 5 Durvalumab-related adverse events

From: Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC

 

Frequency

%

Pneumonitis

6

25.0

G1

1

4.2

G2

3

12.5

G3

2

8.3

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us